When being introduced to the world of market access and health economics, the staggering number of abbreviations can be overwhelming: HTA, QALY, DRG... What should we make of all these terms? And more importantly, how should we interpret them in this dynamic healthcare environment?
During the first stages of the development of a medical device, manufacturers are introduced to the world of market access and health economics. It is essential that they not just focus solely on the clinical benefits, but also examine the maximum cost of their technology to realize an economic benefit. By doing this, developers may already come up with certain questions that can be addressed early on in clinical trials to avoid the cost of duplicated clinical research or useless data.
Download this white paper and discover reimbursement and market access in key markets, success factors, the decision makers, and differences in payment systems.